Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Desert Gold Report Results from 3,900 Meter Phase 2 Exploration Drill Program (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pfizer Inc PFE

Alternate Symbol(s):  N.PFE

Healthcare
Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the... see more

Recent & Breaking News (NYSE:PFE)

Pfizer Announces Positive Top-Line Results From PALOMA-1 Evaluating Palbociclib Plus Letrozole in Women with Advanced Breast Cancer

Business Wire February 3, 2014

New HIV Treatment Launched by ViiV Healthcare Addresses Multiple Evolving Needs of People Living With HIV in the UK

PR Newswire February 3, 2014

Wall Street Fundamentals Releases New In-Depth Stock Reports on CMCSA, F, PFE and YHOO

Accesswire January 29, 2014

Pfizer Reports Fourth-Quarter and Full-Year 2013 Results; Provides 2014 Financial Guidance

Business Wire January 28, 2014

Pfizer Announces Top-Line Results From Two Phase 3 Trials Of Dacomitinib In Patients With Refractory Advanced Non-Small Cell Lung Cancer

Business Wire January 27, 2014

Five Star Equities Issues New Research Reports on GALT, PATH, PETS and PFE

Accesswire January 23, 2014

Pfizer Reports Top-Line Results From ALO-02 Phase 3 Study

Business Wire January 23, 2014

New Survey Reveals What Match.Com Members Think About Smoking Cigarettes And Dating

Business Wire January 22, 2014

CHANTIX®/CHAMPIX® (varenicline) Demonstrates Smoking-Cessation Efficacy In Smokers Unwilling or Unable To Quit Abruptly

Business Wire January 21, 2014

ViiV Healthcare's new HIV medicine Tivicay(TM) (dolutegravir) is approved in Europe

PR Newswire January 21, 2014

Statement from Pfizer Chief Medical Officer on the 50th Anniversary of the First Surgeon General's Report on Smoking and Health

Business Wire January 17, 2014

Merck (MRK) recalls Lipruzet cholesterol drug due to packaging defect

Canadian Press January 14, 2014

Portola Pharmaceuticals Enters Second Clinical Collaboration Agreement With Bristol-Myers Squibb and Pfizer to Study Andexanet Alfa* (PRT4445), Investigational Factor Xa Inhibitor Reversal Agent, With Eliquis

Globe Newswire January 13, 2014

Wall Street Fundamentals Releases New In-Depth Stock Reports on EMC, PFE, VRZ and XRX

Accesswire January 8, 2014

Nodality Enters into a Strategic Collaboration with Johnson & Johnson Innovation in Autoimmune Diseases

Business Wire January 8, 2014

TrendingWallStreet.com Begins Covering GILD, PFE, SKTO, and CSUN

Accesswire December 31, 2013

FDA Accepts For Review ELIQUIS® (apixaban) Supplemental New Drug Application for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and for the Reduction in the Risk of Recurrent DVT and PE

Business Wire December 19, 2013

Surgical Scar Market Is Ripe for Innovation

Accesswire December 18, 2013

Pfizer Settles Viagra® Patent Litigation With Teva

Business Wire December 17, 2013

Pfizer Invites Public To View And Listen To Webcast Of January 28 Conference Call With Analysts

Business Wire December 17, 2013